An observational study in Breast Cancer, sponsored by Liaquat University of Medical & Health Sciences. Status unknown at 2 sites in Pakistan. Per ClinicalTrials.gov, last updated 2021-01-14.
Sponsored by Liaquat University of Medical & Health Sciences · Observational
Null hypothesis: Histological grade of tumour bears no relation with the status of sex hormone receptors.
Alternate hypothesis: Both the histological grade of tumour and expression of sex steroid receptors are directly related to each other The investigators aim to;
Breast cancer accounts for the largest number of deaths amongst the female population worldwide. It is now considered as a systemic disease even if diagnosed at an initial stage, as the clinical behaviour cannot be accurately predicted. Due to this reason, it is subjected to new dimensions of research every day. The aggressiveness of the cancer is directly proportional to the histopathological grade at the time of diagnosis. This is true with reference to the clinical stage at the time of presentation, the probability to metastasize and potential to recur. The idea of steroids receptor expression by the tumour is not new, and to evaluate their status prior to the induction of hormone therapy is a must.
The sex steroids, which are produced intratumorally, include estrogen, progesterone, and androgens. They act on their specific receptors present on the cell surface, within the cytoplasm and at the nuclear membrane. It is a measurement of these receptors that decide the potential of an individual to respond to different types of hormones like estrogen receptor blockers and aromatase inhibitors. Do the histological grade of tumour bears some relation with the status of these receptors and can investigators predict and rely just on the cellular behaviour of tumour for the purpose of prognosis is still under investigation. This study is designed to see the relationship between the histopathological grade of the tumour with the expression of sex steroid receptors. It will also try to evaluate whether these receptors bear some prognostic value or not.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 382 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Liaquat University of Medical & Health Sciences is the lead sponsor of 55 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All the patients irrespective of age, gender and stage of disease will be including once the disease is confirmed after triple assessment. We shall cover the population in the southern part of Pakistan.
Exclusion Criteria:
All the patients irrespective of age, ethnicity and stage of disease will be including once the disease is confirmed after triple assessment
Other: No Intervention
No intervention used. This is observational study
Histopathology of tumour
The incidence of grade and type of breast cancer at the time of study will be recorded and analysed
Time frame: 6 months
Steroid receptor status
The concentrations of estrogen and progesterone receptor will be calculated and analysed.
Time frame: 6 months
Age
The age of patient will be calculated and compared to the primary outcomes.
Time frame: 6 months
State of menstruation
The onset of premenopausal and postmenopausal status of patient will be recorded
Time frame: 6 months
Stage of tumour
The status of clinical and pathological stage of the breast cancer at the time of study will be analysed.
Time frame: 6 months
Plan to share: Undecided — At the moment the facility is undecided about the plans to share the data
This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Liaquat University of Medical & Health Sciences